Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetaminophen for prednisone-induced mood and memory changes
NCT00377364Phase 4
Key facts
- Status
- Completed
- Start
- Nov 2006
- Primary completion
- Oct 2008
- Countries
- 1
- Sponsor
- UT Southwestern Medical Center
- Modality
- Small Molecules
- Drugs
- acetaminophen
- Conditions
- corticosteroid-induced cognitive impairmentcorticosteroid-induced mood disorder
01
Overview
Phase 4, randomised, double-blind trial of acetaminophen in corticosteroid-induced cognitive impairment and corticosteroid-induced mood disorder, sponsored by UT Southwestern Medical Center. Primary endpoint: Rey Auditory Verbal Learning at Day 7. Started Nov 2006; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Adults aged 18-65 scheduled to receive at least 20 mg/day of prednisone for at least 7 days with a baseline RAVLT score of at least 40, excluding those with liver disease, heavy alcohol use, or severe cognitive disorders.
04
Endpoints
Primary
Rey Auditory Verbal Learning
Beyond the preview
Go deeper on NCT00377364.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00377364.